Drug Trial Radar · NCT00030719
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Jun 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
175
Planned (sponsor's estimate)
Start
Dec 2001
Primary completion
Not stated
Sponsor
- Lead sponsor
- University of LeicesterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet known which treatment regimen is more effective in treating neuroblastoma. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed by isotretinoin with or without monoclonal antibody work in treating patients with neuroblastoma.
Conditions
- Neuroblastoma
Interventions
filgrastimBiological
monoclonal antibody Ch14.18Biological
busulfanDrug
carboplatinDrug
cyclophosphamideDrug
etoposideDrug
isotretinoinDrug
melphalanDrug
vincristine sulfateDrug
bone marrow ablation with stem cell supportProcedure
conventional surgeryProcedure
peripheral blood stem cell transplantationProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival at 3 years
- Mean number of febrile events during induction
Locations
32 sites in 13 countries. Site status is shown where the registry gives one.
St. Anna Children's Hospital
Vienna, Austria · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Aarhus Universitetshospital - Aarhus Sygehus
Aarhus, Denmark · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Our Lady's Hospital for Sick Children Crumlin
Dublin, Ireland · Recruiting
Schneider Children's Medical Center of Israel
Petah Tikva, Israel · Recruiting
Fondazione Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
Rikshospitalet University Hospital
Oslo, Norway · Recruiting
Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, SA
Lisbon, Portugal · Recruiting
Hospital Universitario La Fe
Valencia, Spain · Recruiting
Karolinska University Hospital - Solna
Stockholm, Sweden · Recruiting
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland · Recruiting
Birmingham Children's Hospital
Birmingham, England, United Kingdom · Recruiting
Institute of Child Health at University of Bristol
Bristol, England, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, England, United Kingdom · Recruiting
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom · Recruiting
Leicester Royal Infirmary
Leicester, England, United Kingdom · Recruiting
Royal Liverpool Children's Hospital, Alder Hey
Liverpool, England, United Kingdom · Recruiting
Middlesex Hospital
London, England, United Kingdom · Recruiting
Great Ormond Street Hospital for Children
London, England, United Kingdom · Recruiting
Royal Manchester Children's Hospital
Manchester, England, United Kingdom · Recruiting
Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Newcastle upon Tyne, England, United Kingdom · Recruiting
Queen's Medical Centre
Nottingham, England, United Kingdom · Recruiting
Oxford Radcliffe Hospital
Oxford, England, United Kingdom · Recruiting
Children's Hospital - Sheffield
Sheffield, England, United Kingdom · Recruiting
Southampton General Hospital
Southampton, England, United Kingdom · Recruiting
Royal Marsden - Surrey
Sutton, England, United Kingdom · Recruiting
Royal Belfast Hospital for Sick Children
Belfast, Northern Ireland, United Kingdom · Recruiting
Royal Aberdeen Children's Hospital
Aberdeen, Scotland, United Kingdom · Recruiting
Royal Hospital for Sick Children
Edinburgh, Scotland, United Kingdom · Recruiting
Royal Hospital for Sick Children
Glasgow, Scotland, United Kingdom · Recruiting
Childrens Hospital for Wales
Cardiff, Wales, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.